Market Overview

AstraZeneca's Drug Combo To Treat Non-Small Cell Lung Cancer Stumbles In Late-Stage Study

Share:
AstraZeneca's Drug Combo To Treat Non-Small Cell Lung Cancer Stumbles In Late-Stage Study

AstraZeneca plc (NYSE: AZN) faced a clinical setback in a study evaluating a combo drug regimen in non-small cell lung cancer, or NSCLC.

What Happened

AstraZeneca said a Phase 3 study dubbed NEPTUNE that evaluated its PD-LI inhibitor Imfinzi in combination with tremelimumab, an anti-CTLA4 antibody, versus platinum-based chemotherapy – the current standard-of-care- in previously untreated Stage IV NSCLC did not meet the primary endpoint of improving overall survival.

The company noted that the primary analysis population was patients with a high tumor mutational burden.

The safety and tolerability profile of the combo, however, was consistent with previous trials.

What's Next

AstraZeneca said it intends to do a deep analysis of the vast clinical and biomarker data from the trial to gain further insights to improve Immuno-oncology approaches for patients with metastatic NSCLC. The company will submit the full results for presentation at a forthcoming medical meeting.

Imfinzi is also being tested as monotherapy in a Phase 3 trial, dubbed PEARL, and in combination with chemotherapy with or without tremelimumab in the Phase 3 trial, dubbed POSEIDON, as part of an extensive late-stage Immuno-oncology program in Stage IV NSCLC.

Notwithstanding the negative catalyst, AstraZeneca shares were up 1.1% to $45.13& Wednesday morning.

Related Links:

The Daily Biotech Pulse: Ra Medical Earns Milestone, Aimmune Doses Patient In Egg Allergy Trial, Cara In-Licenses Platform

Biotech Stock On The Radar: Medicines Company, A Cardiovascular Pure Play With A Potential Blockbuster

Posted-In: News Health Care Trading Ideas General Best of Benzinga

 

Related Articles (AZN)

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com